William Blair Upgrades Ionis Pharmaceuticals to Outperform
William Blair analyst Myles Minter upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform.
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $36
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $39 to $36.
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has enter
Barron’s Most Recent Picks And Pans: General Electric, Pfizer, Walt Disney And More
This weekend's Barron's cover story examines the revival of mall stocks.
Other featured articles discuss why small-cap stocks are the next big thing and some energy stocks that are poised to double.
Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $60
Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $84 to $60.
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $39
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $38 to $39.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.